Compare Moderna, Inc. (MRNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Koninklijke Philips NV — how do they compare? Moderna, Inc. trades at $61.96 (market cap $24.18B), while Koninklijke Philips NV trades at $26.56 (market cap $26.58B). The key difference: Moderna, Inc. and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PHG | |
|---|---|---|
Market Cap | $24.18B | $26.58B |
Sector | Health | Health |
52-Week High | $81.80 | $32.91 |
52-Week Low | $22.36 | $25.02 |
Enterprise Value | $20.33B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
PHG trades at $26.94, up 0.79% with bullish technical signals and strong earnings beats in recent quarters. The company shows improving fundamentals with 2025 net income of $895M (5.01% margin) and positive cash flow trends. Recent news highlights Exor's increased stake flexibility and institutional buying interest, supporting positive sentiment despite some order timing challenges.
The outlook remains constructive with analyst consensus leaning positive (40.9% buy ratings) and improving profitability. Key risks include competitive pressures and macroeconomic headwinds, but solid execution and shareholder support provide stability for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
